CATAPRES TAB 0.1MG TABLET
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
06-07-2012
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
CLONIDINE HYDROCHLORIDE
Tillgänglig från:
BOEHRINGER INGELHEIM (CANADA) LTD LTEE
ATC-kod:
C02AC01
INN (International namn):
CLONIDINE
Dos:
0.1MG
Läkemedelsform:
TABLET
Sammansättning:
CLONIDINE HYDROCHLORIDE 0.1MG
Administreringssätt:
ORAL
Enheter i paketet:
100
Receptbelagda typ:
Prescription
Terapiområde:
CENTRAL ALPHA-AGONISTS
Produktsammanfattning:
Active ingredient group (AIG) number: 0108891001; AHFS:
Bemyndigande status:
CANCELLED POST MARKET
Tillstånd datum:
2017-02-15
Produktens egenskaper
_Catapres_
_®_
_ Product Monograph _
_Page 1 of 29_
PRODUCT MONOGRAPH
PR
CATAPRES
®
(Clonidine Hydrochloride)
Boehringer Ingelheim Standard
TABLETS
0.1
mg, 0.2 mg
Antihypertensive
Boehringer Ingelheim (Canada) Ltd
5180 South Service Road
Burlington, Ontario
L7L 5H4
Date of Revision:
June 21, 2012
SUBMISSION CONTROL NO: 154435
Catapres
®
is a registered trademark used under license by Boehringer Ingelheim
(Canada) Ltd.
CCDS 0067-03
_ _
_Catapres_
_®_
_ Product Monograph _
_Page 2 of 29 _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................11
OVERDOSAGE
................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
............................................................13
STORAGE AND STABILITY
..........................................................................................15
DOSAGE FORMS, COMPOSITION AND
PACKAGING.............................................15
PART II: SCIENTIFIC INFORMATION
...............................................................................16
PHARMACEUTICAL INFORMATION
..........................................................................16
DET
Läs hela dokumentet
